
Takeda Pharmaceutical
TKPHF | OTC
$36.77
+$0.02 (+0.05%)
At close: Oct 2, 2026, 3:04 PM ET
Takeda Pharmaceutical Company Profile
Company profile explainedCompany Profile
Takeda Pharmaceutical Company Limited, an established global biopharmaceutical entity founded in 1781 and based in Tokyo, Japan, is comprehensively involved in the entire process of bringing new medicines to market. This includes the research, development, production, commercialization, and external licensing of its pharmaceutical products across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and other parts of Asia. The company concentrates its therapeutic endeavors on key medical areas such as digestive health (gastroenterology), rare disorders, treatments derived from blood plasma, cancer care (oncology), and neurological conditions. Its extensive portfolio features numerous well-known brands, including Entyvio, Takhzyro, Velcade, Livtencity, and Dexilant, among others. Takeda actively cultivates a wide-ranging network of strategic partnerships and collaborations. This includes out-licensing agreements, for example with Neurocrine Biosciences, Inc.; in-licensing deals and research collaborations with organizations like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and joint research efforts with companies such as Crescendo Biologics and Skyhawk Therapeutics. Furthermore, Takeda maintains strategic alliances with entities like Evotec SE and KSQ Therapeutics, underscoring its commitment to external innovation.
Key Executives
| Name | Position |
|---|---|
| Julie Kim | CEO, President & Director |
| Michael Fox | Chief Operating Officer |
| Milano Furuta | Chief Financial Officer & Director |
| Andrew S. Plump | President of Research & Development and Representative Director |
| Gabriele Ricci | Chief Data & Technology Officer |
| Haruhiko Hirate | Member of Management Board |
| Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Seigo Izumo | Chair of Management Board |
Takeda Pharmaceutical

| Country | Japan |
| IPO Date | Jun 25, 2008 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 47,029 |
| CEO | Julie So-Young Kim |
Contact Details
1-1, Nihonbashi-Honcho 2-chome Tokyo,
OS 103-8668 Japan
Stock Details
| Ticker Symbol | TKPHF |
| Exchange | OTC |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001395064 |
| CUSIP Number | n/a |
| ISIN Number | JP3463000004 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove TKPHF